GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » TearLab Corp (OTCPK:TEAR) » Definitions » Piotroski F-Score

TearLab (TearLab) Piotroski F-Score : 0 (As of Apr. 26, 2024)


View and export this data going back to 2004. Start your Free Trial

What is TearLab Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

TearLab has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for TearLab's Piotroski F-Score or its related term are showing as below:


TearLab Piotroski F-Score Historical Data

The historical data trend for TearLab's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TearLab Piotroski F-Score Chart

TearLab Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 5.00 3.00 6.00 3.00

TearLab Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 6.00 5.00 3.00 3.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar20) TTM:Last Year (Mar19) TTM:
Net Income was -1.174 + -1.75 + -1.152 + -1.566 = $-5.64 Mil.
Cash Flow from Operations was 0.344 + 0.265 + -1.961 + 0.425 = $-0.93 Mil.
Revenue was 5.851 + 5.628 + 5.493 + 5.091 = $22.06 Mil.
Gross Profit was 3.689 + 3.539 + 3.47 + 3.23 = $13.93 Mil.
Average Total Assets from the begining of this year (Mar19)
to the end of this year (Mar20) was
(15.484 + 15.939 + 15.919 + 14.293 + 14.072) / 5 = $15.1414 Mil.
Total Assets at the begining of this year (Mar19) was $15.48 Mil.
Long-Term Debt & Capital Lease Obligation was $0.39 Mil.
Total Current Assets was $11.67 Mil.
Total Current Liabilities was $41.12 Mil.
Net Income was -0.661 + -0.195 + -0.512 + -1.339 = $-2.71 Mil.

Revenue was 6.413 + 6.152 + 5.988 + 5.683 = $24.24 Mil.
Gross Profit was 3.793 + 3.769 + 3.658 + 3.6 = $14.82 Mil.
Average Total Assets from the begining of last year (Mar18)
to the end of last year (Mar19) was
(13.712 + 12.305 + 13.756 + 14.513 + 15.484) / 5 = $13.954 Mil.
Total Assets at the begining of last year (Mar18) was $13.71 Mil.
Long-Term Debt & Capital Lease Obligation was $25.90 Mil.
Total Current Assets was $12.80 Mil.
Total Current Liabilities was $11.45 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

TearLab's current Net Income (TTM) was -5.64. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

TearLab's current Cash Flow from Operations (TTM) was -0.93. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar19)
=-5.642/15.484
=-0.36437613

ROA (Last Year)=Net Income/Total Assets (Mar18)
=-2.707/13.712
=-0.19741832

TearLab's return on assets of this year was -0.36437613. TearLab's return on assets of last year was -0.19741832. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

TearLab's current Net Income (TTM) was -5.64. TearLab's current Cash Flow from Operations (TTM) was -0.93. ==> -0.93 > -5.64 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar20)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar19 to Mar20
=0.392/15.1414
=0.02588928

Gearing (Last Year: Mar19)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar18 to Mar19
=25.899/13.954
=1.85602695

TearLab's gearing of this year was 0.02588928. TearLab's gearing of last year was 1.85602695. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar20)=Total Current Assets/Total Current Liabilities
=11.668/41.124
=0.28372726

Current Ratio (Last Year: Mar19)=Total Current Assets/Total Current Liabilities
=12.797/11.448
=1.11783718

TearLab's current ratio of this year was 0.28372726. TearLab's current ratio of last year was 1.11783718. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

TearLab's number of shares in issue this year was 12.561. TearLab's number of shares in issue last year was 11.559. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=13.928/22.063
=0.63128314

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=14.82/24.236
=0.61148704

TearLab's gross margin of this year was 0.63128314. TearLab's gross margin of last year was 0.61148704. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar19)
=22.063/15.484
=1.42489021

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar18)
=24.236/13.712
=1.76750292

TearLab's asset turnover of this year was 1.42489021. TearLab's asset turnover of last year was 1.76750292. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+0+1+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

TearLab has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

TearLab  (OTCPK:TEAR) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


TearLab Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of TearLab's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


TearLab (TearLab) Business Description

Traded in Other Exchanges
N/A
Address
150 LaTerraza Boulevard, Suite 101, Escondido, CA, USA, 92025
TearLab Corp is a part of the diagnostic industry. It is an in-vitro diagnostic company based in the United States. TearLab has commercialized a proprietary tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for highly sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The company operates through its wholly-owned subsidiary, TearLab Research Inc. Most of the company's revenue is derived from the United States region.
Executives
Anthony E Altig director C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, JERSEY CITY NJ 07302
Cr Group L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Lindstrom Richard L Md director 2811 WESTWOOD PL, WAYZATA MN 55391
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Adrienne L Graves director 125 STONE MOUNTAIN CIRCLE, NAPA CA 94558
Gilbert S Omenn director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
John Y Caloz officer: Chief Financial Officer ETON AVE, C/O INTERNATIONAL REMOTE IMAGING SYS, CHATSWORTH CA 91311